Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > This $3 BioTech Stock could EXPLODE SOON!! Why?

<< Previous

Bullboard Posts

Next >>

Comment by MasterAlgaeon Jun 11, 2021 11:48am

127 Views

Post# 33372436

RE:RE:RE:RE:RE:RE:This $3 BioTech Stock could EXPLODE SOON!! Why?

Wow they do know about it, and they/we did pay for it....

MasterAlgae wrote: I agree with your points Mugs - Note: Antibe did not pay for this video, they may not even be aware of it. It says a third party paid for it. Not sure who that could be, if indeed it is true...

MrMugsy wrote:

Hey ... I'm not knocking the video ... it was fun for existing shareholders to watch and I appreciate it being posted because it's killing some time for us.

But ... that's not going to gain us any traction going forward - IMO. It carried pics and video clips that made 95% of the visual unrelated to ATE - just fluff that could have been added to almost any science discussion for a high school presentation. The biggest benefit was the excitement in his voice but in the end ... he was just repeating what he understood from reading the presentation.

It's great that others are doing this ... just not where the company really needs to focus.

Product development, drug advancement and negotiations will drive our value in the short to medium term - IMO. The two investors we should really focus on right now is the Institutional Investor and the drug partners. The retail investor will just follow along once that happens.

Cheers to the rest of 2021 to get things done !!!